CFCS-associated mutations affecting the BRAF, MAP2K1, MAP2K2 and KRAS genes are predicted to cause an enhanced activation of signalling through the RAS-MAPK pathway [4]. This evidence concerns the gene BRAF and cardiofaciocutaneous syndrome 1.